ClinicalTrials.gg
CompletedNCT01382940RATE-RAUpdated Aug 1, 2017Results posted

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis

A Phase 4 interventional study of rituximab and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 86 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-01.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
351
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
12th of 63
351 · median 159
Started
2011
with 3 others
Phase 4
14 of 63
3 open now
Registered
33rd of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 12th largest by enrollment, is one of 4 that started in 2011, is one of 14 in phase 4, and was the 33rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study was designed to evaluate the safety of administering rituximab at a more rapid infusion rate in patients with moderate to severe rheumatoid arthritis who have had an inadequate response to biopharmaceuticals that treat diseases by interfering with tumor necrosis factor (anti-TNF therapies), and were receiving methotrexate therapy for more than eight weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adult patients, ≥ 18 years of age
  • Rheumatoid arthritis of ≥ 6 months duration, diagnosed according to the revised 1987 American College of Rheumatology criteria
  • Inadequate response to at least one approved anti-TNF agent (adalimumab, etanercept, infliximab, golimumab, or certolizumab)
  • Patients who have received 1 to 2 prior courses of rituximab (RTX) may be enrolled, provided their most recent course of RTX occurred over 6 months but no more than 9 months prior to baseline. The RTX dosage must have been two 1000 mg infusions per course administered at the standard approved rate
  • Methotrexate treatment between 10 and 25 mg/week (oral or parenteral) for at least 8 weeks immediately prior to baseline

Key Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned surgery within 6 months following baseline
  • Rheumatic disease other than rheumatoid arthritis
  • Functional class IV as defined by American College of Rheumatology (ACR) criteria
  • Prior history of or current inflammatory joint disease other than rheumatoid arthritis
  • History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies
  • Previous serious infusion reaction to any prior biologic therapy
  • Known active current or history of recurrent infection
  • Evidence of chronic or C infection
  • Pregnant or lactating women
  • Body weight of > 150 kg
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
351 participants (actual)

Study arms

  • Experimental
    Rituximab

    Rituximab intravenous (IV) infusions were administered over a 4.25-hour period on Day 1, and over a 2-hour period on Day 15 (first course) and on Days 168 and 182 (second course). All participants continued to receive methotrexate as prescribed by their treating physician. Premedication included methylprednisolone, an antihistamine and acetaminophen.

    Drug: rituximab · Drug: methotrexate · Drug: methylprednisolone · Drug: acetaminophen · Drug: antihistamine

Interventions

  • 1000 mg in 250 mL intravenous infusion

    Also known as: Rituxan®, MabThera®

  • 10 to 25 mg/week (oral or parenteral)

  • 100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion

  • 1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion

  • 50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Any Infusion-related Reaction (IRR) Associated With the Second Rituximab Infusion

    The primary criterion for assessing safety of the faster infusion was the incidence of infusion related reaction (IRRs). IRRs were adverse events (AEs) that occurred within 24 hours of beginning infusion that were among a pre-specified list of preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA). "Incidence" is defined as the percentage of participants experiencing an IRR.

    Time frame: Within 24 hours of beginning infusion on Day 15

Secondary outcomes

  1. Percentage of Participants Experiencing Any Serious IRR (SIRR) Associated With the Second Rituximab Infusion

    A serious infusion-related reaction (SIRR) is an IRR that meets the definition of a serious adverse event. A serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution.

    Time frame: Within 24 hours of beginning infusion on Day 15

  2. Percentage of Participants Experiencing Any IRR or SIRR Associated With the Third Rituximab Infusion

    IRRs are AEs that occurred within 24 hours of beginning infusion that were included on a pre-specified list of MedDRA preferred terms, and an SIRR is an IRR that suggests a significant hazard, contraindication, side effect or precaution.

    Time frame: Within 24 hours of beginning infusion on Day 168

  3. Percentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Second Rituximab Infusion

    The intensity of AEs were graded on a 5-point scale (Grade 1 to 5) according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v. 4.0), where Grade 1 indicates "Mild" severity and Grade 5 indicates "Death". The CTCAE defines Grades 3 and 4 as follows: - Grade 3 means "Severe", indicating considerable interference with the patient's daily activities; medical intervention/therapy required; and hospitalization possible. - Grade 4 means "Life-threatening, Disabling", based on extreme limitation in activity; significant medical intervention/therapy required, and hospitalization probable.

    Time frame: Within 24 hours of beginning infusion on Day 15

  4. Percentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Second Rituximab Infusion

    Participants who experienced a moderate or serious IRR had their infusion interrupted immediately and received aggressive symptomatic treatment. The CTCAE includes the following severity descriptions: - "Moderate" means mild to moderate interference with the patient's daily activities, no or minimal medical intervention/therapy required; - "Severe" means considerable interference with the patient's daily activities, medical intervention/therapy required, hospitalization possible. If the IRR was moderate, the infusion was not to be restarted before all the symptoms disappeared, and then at half the rate. If the participant tolerated the reduced rate for 30 minutes, the infusion rate was increased to the next rate on the protocol-specified infusion schedule. If the symptoms did not resolve with treatment, the participant was withdrawn from the treatment period of the study. Participants who experienced a severe IRR to rituximab treatment were discontinued from the study.

    Time frame: During the infusion (a 2-hour period) on Day 15

  5. Percentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Third Rituximab Infusion

    The intensity of AEs experienced within 24 hours of beginning infusion were graded on NCI's CTCAE (v. 4.0) intensity scale from Grade 1 ("Mild") to Grade 5 ("Death"). Grade 3 AEs are "Severe" and Grade 4 AEs are "Life-threatening, Disabling".

    Time frame: Within 24 hours of beginning infusion on Day 168

  6. Percentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Third Rituximab Infusion

    Participants who experienced a moderate or serious IRR had their infusion interrupted immediately and received aggressive symptomatic treatment. The CTCAE includes the following severity descriptions: - "Moderate" means mild to moderate interference with the patient's daily activities, no or minimal medical intervention/therapy required; - "Severe" means considerable interference with the patient's daily activities, medical intervention/therapy required, hospitalization possible. If the IRR was moderate, the infusion was not to be restarted before all the symptoms disappeared, and then at half the rate. If the participant tolerated the reduced rate for 30 minutes, the infusion rate was increased to the next rate on the protocol-specified infusion schedule. If the symptoms did not resolve with treatment, the participant was withdrawn from the treatment period of the study. Participants who experienced a severe IRR to rituximab treatment were discontinued from the study.

    Time frame: During the infusion (a 2-hour period) on Day 168

07

Results

Posted Feb 19, 2014

Participant flow

Participant flow — Overall Study
MilestoneRituximab
Started351
Received day 1 infusion351
Received day 15 infusions341
Received day 168 infusion290
Received day 182 infusion278
Completed278
Not completed73
Withdrew: Adverse event19
Withdrew: Lost to follow-up4
Withdrew: Physician decision7
Withdrew: Withdrawal by subject23
Withdrew: Protocol violation20

Outcome measures

PrimaryPercentage of Participants Experiencing Any Infusion-related Reaction (IRR) Associated With the Second Rituximab Infusion

The primary criterion for assessing safety of the faster infusion was the incidence of infusion related reaction (IRRs). IRRs were adverse events (AEs) that occurred within 24 hours of beginning infusion that were among a pre-specified list of preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA). "Incidence" is defined as the percentage of participants experiencing an IRR.

Time frame:
Within 24 hours of beginning infusion on Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Any Infusion-related Reaction (IRR) Associated With the Second Rituximab Infusion
percentage of participantsRituximab
Percentage of Participants Experiencing Any Infusion-related Reaction (IRR) Associated With the Second Rituximab Infusion6.5 ± 6.5
SecondaryPercentage of Participants Experiencing Any Serious IRR (SIRR) Associated With the Second Rituximab Infusion

A serious infusion-related reaction (SIRR) is an IRR that meets the definition of a serious adverse event. A serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution.

Time frame:
Within 24 hours of beginning infusion on Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Any Serious IRR (SIRR) Associated With the Second Rituximab Infusion
percentage of participantsRituximab
Percentage of Participants Experiencing Any Serious IRR (SIRR) Associated With the Second Rituximab Infusion0.0 (0.0 to 1.1)
SecondaryPercentage of Participants Experiencing Any IRR or SIRR Associated With the Third Rituximab Infusion

IRRs are AEs that occurred within 24 hours of beginning infusion that were included on a pre-specified list of MedDRA preferred terms, and an SIRR is an IRR that suggests a significant hazard, contraindication, side effect or precaution.

Time frame:
Within 24 hours of beginning infusion on Day 168
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Any IRR or SIRR Associated With the Third Rituximab Infusion
percentage of participantsRituximab
Any IRR5.9 (3.5 to 9.3)
Any SIRR0.0 (0.0 to 1.3)
SecondaryPercentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Second Rituximab Infusion

The intensity of AEs were graded on a 5-point scale (Grade 1 to 5) according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v. 4.0), where Grade 1 indicates "Mild" severity and Grade 5 indicates "Death". The CTCAE defines Grades 3 and 4 as follows: - Grade 3 means "Severe", indicating considerable interference with the patient's daily activities; medical intervention/therapy required; and hospitalization possible. - Grade 4 means "Life-threatening, Disabling", based on extreme limitation in activity; significant medical intervention/therapy required, and hospitalization probable.

Time frame:
Within 24 hours of beginning infusion on Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Second Rituximab Infusion
percentage of participantsRituximab
Percentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Second Rituximab Infusion0.6 (0.1 to 2.1)
SecondaryPercentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Second Rituximab Infusion

Participants who experienced a moderate or serious IRR had their infusion interrupted immediately and received aggressive symptomatic treatment. The CTCAE includes the following severity descriptions: - "Moderate" means mild to moderate interference with the patient's daily activities, no or minimal medical intervention/therapy required; - "Severe" means considerable interference with the patient's daily activities, medical intervention/therapy required, hospitalization possible. If the IRR was moderate, the infusion was not to be restarted before all the symptoms disappeared, and then at half the rate. If the participant tolerated the reduced rate for 30 minutes, the infusion rate was increased to the next rate on the protocol-specified infusion schedule. If the symptoms did not resolve with treatment, the participant was withdrawn from the treatment period of the study. Participants who experienced a severe IRR to rituximab treatment were discontinued from the study.

Time frame:
During the infusion (a 2-hour period) on Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Second Rituximab Infusion
percentage of participantsRituximab
Percentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Second Rituximab Infusion3.9 (2.1 to 6.5)
SecondaryPercentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Third Rituximab Infusion

The intensity of AEs experienced within 24 hours of beginning infusion were graded on NCI's CTCAE (v. 4.0) intensity scale from Grade 1 ("Mild") to Grade 5 ("Death"). Grade 3 AEs are "Severe" and Grade 4 AEs are "Life-threatening, Disabling".

Time frame:
Within 24 hours of beginning infusion on Day 168
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Third Rituximab Infusion
percentage of participantsRituximab
Percentage of Participants Experiencing Any Common Toxicity Criteria (CTC) Grade 3 or 4 Adverse Events (AEs) Associated With the Third Rituximab Infusion0.0 (0.0 to 1.3)
SecondaryPercentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Third Rituximab Infusion

Participants who experienced a moderate or serious IRR had their infusion interrupted immediately and received aggressive symptomatic treatment. The CTCAE includes the following severity descriptions: - "Moderate" means mild to moderate interference with the patient's daily activities, no or minimal medical intervention/therapy required; - "Severe" means considerable interference with the patient's daily activities, medical intervention/therapy required, hospitalization possible. If the IRR was moderate, the infusion was not to be restarted before all the symptoms disappeared, and then at half the rate. If the participant tolerated the reduced rate for 30 minutes, the infusion rate was increased to the next rate on the protocol-specified infusion schedule. If the symptoms did not resolve with treatment, the participant was withdrawn from the treatment period of the study. Participants who experienced a severe IRR to rituximab treatment were discontinued from the study.

Time frame:
During the infusion (a 2-hour period) on Day 168
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Third Rituximab Infusion
percentage of participantsRituximab
Percentage of Participants Experiencing the Stopping, Slowing or Interrupting of the Third Rituximab Infusion6.6 (4.0 to 10.1)

Adverse events

Collected over Adverse events were collected at each visit and during a follow-up telephone visit four weeks after the last rituximab infusion (Day 210).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab—30/351 (8.5%)37/351 (10.5%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventRituximab
PneumoniaInfections and infestations4/351
Atrial fibrillationCardiac disorders2/351
Hip fractureInjury, poisoning and procedural complications2/351
Rheumatoid arthritisMusculoskeletal and connective tissue disorders2/351
Febrile neutropeniaBlood and lymphatic system disorders1/351
Cardiac failure congestiveCardiac disorders1/351
Myocardial infarctionCardiac disorders1/351
Pericardial effusionCardiac disorders1/351
Deafness neurosensoryEar and labyrinth disorders1/351
Colitis ischaemicGastrointestinal disorders1/351
Most frequent other events
Most frequent other events
EventRituximab
HeadacheNervous system disorders20/351
Upper Respiratory Tract InfectionInfections and infestations19/351

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rituximab
Mean55.5 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab
Female279
Male72
08

Study locations

86 sites
  • Uni Of Alabama,Birmingham; Medicine - Rheumatology
    Birmingham, Alabama 35294, United States
  • Clnical & Translational Reseach Center for Alabama, PC
    Tuscaloosa, Alabama 35406, United States
  • ArthroCare, Arthritis Care; and Research P.C.
    Gilbert, Arizona 85234, United States
  • Valley Arthritis Care
    Phoenix, Arizona 85027, United States
  • Catalina Pointe Rheumatology
    Tucson, Arizona 85704, United States
  • Medvin Clinical Research
    Covina, California 91723, United States
  • Triwest Research Associates
    La Mesa, California 91942, United States
  • Medvin Clinical Research
    Los Angeles, California 90048, United States
  • Brigid Freyne-Private Practice; Internal Medicine, Rheum
    Murrieta, California 92563, United States
  • Desert Medical Advances; Rheumatology
    Palm Desert, California 92260, United States
  • San Diego Arthritis Med Clnc
    San Diego, California 92108, United States
  • Pacific Arthritis Ctr Med Grp
    Santa Maria, California 93454, United States
  • Inland Rheumatology; Clinical Trials, Inc.
    Upland, California 91786, United States
  • Medvin Clinical Research
    Whittier, California 90606, United States
  • Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs
    Colorado Springs, Colorado 80920, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230-7127, United States
  • Rheum & Internal Med Assoc-Bri
    Bridgeport, Connecticut 06606, United States
  • Arthritis & Osteoporosis Center Pc
    Hamden, Connecticut 06518, United States
  • Rheumatolgy Consultants of Deleware
    Lewes, Delaware 19958, United States
  • Javed Rheumatology Associates, Inc.
    Newark, Delaware 19713, United States
  • Arthritis & Rheumatism; Disease Specialities
    Aventura, Florida 33180, United States
  • Florida Arthritis Center, PI
    Lake Mary, Florida 32746, United States
  • Omega ResearchConsultants LLC
    Orlando, Florida 32804, United States
  • Millenium Research
    Ormond Beach, Florida 32174, United States
  • Arthritis Center Palm Harbor
    Palm Harbor, Florida 34684, United States
  • Arthritis Rsrch of Florida, Inc.
    Palm Harbor, Florida 34684, United States
  • Center For Arthritis; Research Dept
    South Miami, Florida 33143, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Florida Medical Clinic; Clinical Research
    Zephyrhills, Florida 33613, United States
  • Parris & Associates
    Lawrenceville, Georgia 30046, United States
  • St. Luke's Intermountain Research Center
    Boise, Idaho 83702, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • Quad City Rheumatology, Sc
    Moline, Illinois 61265, United States
  • Physician'S Clinic of Iowa
    Cedar Rapids, Iowa 52401, United States
  • Bluegrass Comm Research, Inc.
    Lexington, Kentucky 40515, United States
  • Klein & Associates, M.D. P.A.
    Cumberland, Maryland 21502, United States
  • Klein & Associates, M.D., P.A.
    Hagerstown, Maryland 21740, United States
  • St. Luke's Hospital Association of Duluth
    Duluth, Minnesota 55805, United States
  • Arthritis and Osteoporosis; Treatment and Research Center
    Flowood, Mississippi 39232, United States
  • Jackson Arthritis Clinic
    Flowood, Mississippi 39232, United States
  • North Mississippi Med Clinics, Inc.
    Tupelo, Mississippi 38801, United States
  • David S Rosenberg
    Florissant, Missouri 63031, United States
  • Arthritis Center of Reno
    Reno, Nevada 89502, United States
  • Rheumatology Research Group
    Lebanon, New Hampshire 03756, United States
  • Rheumatology Associates Of New Jersey
    Teaneck, New Jersey 07666, United States
  • The Center for Rheumatology
    Albany, New York 12203, United States
  • Arthritis & Osteoporosis Center
    Brooklyn, New York 11201, United States
  • NYU Center for Musculoskeletal Care
    New York, New York 10003, United States
  • Buffalo Rheumatology Associates
    Orchard Park, New York 14127, United States
  • Office of Premier Chatpar Md
    Plainview, New York 11803, United States
  • Aair Research Center
    Rochester, New York 14618, United States
  • Rheumatology Associates of Long Island
    Smithtown, New York 11787, United States
  • Arthritis Health Associates; Clinical Research
    Syracuse, New York 13210, United States
  • Arth&OsteoConsof theCarolinas-Charlotte
    Charlotte, North Carolina 28207, United States
  • Box Arthritis & Rheumatology
    Charlotte, North Carolina 28210, United States
  • Carolina Bone & Joint P.A.
    Charlotte, North Carolina 28210, United States
  • Physicians East Pa
    Greenville, North Carolina 27834, United States
  • Shanahan Rheumatology & Immunology, PLLC
    Raleigh, North Carolina 27617, United States
  • Crystal Arthritis Center, Inc.
    Akron, Ohio 44333, United States
  • CarePoint East
    Columbus, Ohio 43203, United States
  • Stat Research, Inc
    Dayton, Ohio 45402, United States
  • Paramount Medical Research
    Middleburg Heights, Ohio 44130, United States
  • LION Research
    Norman, Oklahoma 73069, United States
  • Arthritis and Rheumatology; Center of Oklahoma PLLC
    Oklahoma City, Oklahoma 73103, United States
  • East Penn Rheumatology Associates, Pc
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Pivotal Clinical Research, Llc
    Perkasie, Pennsylvania 18944, United States
  • Arthritis Group
    Philadelphia, Pennsylvania 19152, United States
  • Rheumatic Disease Associates; Clinical Research Unit
    Willow Grove, Pennsylvania 19090, United States
  • Clinical Research Center of Reading
    Wyomissing, Pennsylvania 19610, United States
  • Pennsylvania Regional Center for Arthritis and Osteoporosis Research
    Wyomissing, Pennsylvania 19610, United States
  • Low Country Rheumatology, PA
    Charleston, South Carolina 29406, United States
  • Rheumatology Associates
    Charleston, South Carolina 29407, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Ramesh Gupta - PP
    Memphis, Tennessee 38119, United States
  • Amarillo Center For Clinical Research
    Amarillo, Texas 79124, United States
  • Lovelace Scientific Resources Inc.
    Austin, Texas 78758, United States
  • Adriana Pop-Moody MD Clinic PA
    Corpus Christi, Texas 78404, United States
  • Arthritis Centers of Texas
    Dallas, Texas 75246, United States
  • Southwest Rheumatology
    Mesquite, Texas 75150, United States
  • Arthritis Clinic of Northern Virginia
    Arlington, Virginia 22205, United States
  • Apex Clinical Research
    Kennewick, Washington 99336, United States
  • Seattle Arthritis Clinic
    Seattle, Washington 98133, United States
  • Arthritis Northwest, Spokane
    Spokane, Washington 99204, United States
  • Cedar Medical Center
    Tacoma, Washington 98405, United States
  • Rheumatic Disease Center
    Glendale, Wisconsin 53217, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Jan 2013, 17 months.

Results were first posted in Feb 2014, 1 year 1 month after primary completion.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 17 months is below that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2011
First posted
Jun 27, 2011
StartActual
Jul 26, 2011
Primary completionActual
Jan 6, 2013
CompletionActual
Jan 6, 2013
Results first posted
Feb 19, 2014
Last update
Aug 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01382940
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 27, 2011
Start date
Jul 26, 2011
Primary completion
Jan 6, 2013
Completion
Jan 6, 2013
Results posted
Feb 19, 2014
Last update
Aug 1, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion